Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high-risk for preterm delivery

Baha Sibai, Paul J. Meis, Mark Klebanoff, Mitchell P. Dombrowski, Steven J. Weiner, Atef H. Moawad, Allison Northen, Jay D. Iams, Michael W. Varner, Steve N. Caritis, Mary J. O'Sullivan, Menachem Miodovnik, Kenneth J. Leveno, Deborah Conway, Ronald J. Wapner, Marshall Carpenter, Brian Mercer, Susan M. Ramin, John M. Thorp, Alan M. PeacemanSteven Gabbe

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Objective: The purpose of this study was to examine the utility of a single second-trimester plasma corticotropin-relasing hormone measurement as a marker for preterm delivery in women at high risk for preterm delivery. Study design: This is an analysis of data from a multicenter placebo-controlled trial designed to evaluate the role of 17 alpha hydroxyprogesterone caproate (17P) in the prevention of recurrent preterm birth. Women with a documented history of a previous spontaneous preterm birth at <37 weeks were enrolled (16-20 wks) and randomly assigned in a 2 to 1 ratio to weekly injections of 17P or matching placebo. Blood was collected before treatment in 170 patients (113 assigned 17P and 57 placebo) who were enrolled at 11 of the 19 centers. Plasma levels of corticotropin-releasing hormone were compared between those who delivered preterm and those delivering at term. Data were analyzed using the Wilcoxon rank-sum test. Results: The overall rates of preterm birth in this cohort of 170 patients were 35.9% at <37 weeks (31.9% progesterone, 43.9% placebo), and 19.4% at <35 weeks (18.6% vs 21.1%). The median levels of corticotropin-releasing hormone were similar between those delivering at <37 weeks and those delivering ≥37 weeks (0.39 ng/mL vs 0.37 ng/mL, P = .08). In addition, there were no differences in corticotropin-releasing hormone levels among those who delivered at <35 weeks or ≥35 weeks (0.36 vs 0.38, P = .90). Moreover, there were no differences in corticotropin-releasing hormone levels among those in the placebo group who delivered at <37 or ≥37 weeks (0.40 vs 0.41, P = .72) and at <35 or ≥35 weeks (P = .64). Conclusion: A single measurement of corticotropin-releasing hormone at 16 to 20 weeks' gestation is not a good biomarker for recurrent preterm delivery in patients at high risk for this complication.

Original languageEnglish (US)
Pages (from-to)1181-1186
Number of pages6
JournalAmerican Journal of Obstetrics and Gynecology
Volume193
Issue number3 SUPPL.
DOIs
StatePublished - Sep 2005

Fingerprint

Corticotropin-Releasing Hormone
Placebos
Premature Birth
Pregnancy
Nonparametric Statistics
Second Pregnancy Trimester
Adrenocorticotropic Hormone
Progesterone
Biomarkers
Hormones
Injections

Keywords

  • CRH levels
  • Prediction
  • Preterm delivery

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high-risk for preterm delivery. / Sibai, Baha; Meis, Paul J.; Klebanoff, Mark; Dombrowski, Mitchell P.; Weiner, Steven J.; Moawad, Atef H.; Northen, Allison; Iams, Jay D.; Varner, Michael W.; Caritis, Steve N.; O'Sullivan, Mary J.; Miodovnik, Menachem; Leveno, Kenneth J.; Conway, Deborah; Wapner, Ronald J.; Carpenter, Marshall; Mercer, Brian; Ramin, Susan M.; Thorp, John M.; Peaceman, Alan M.; Gabbe, Steven.

In: American Journal of Obstetrics and Gynecology, Vol. 193, No. 3 SUPPL., 09.2005, p. 1181-1186.

Research output: Contribution to journalArticle

Sibai, B, Meis, PJ, Klebanoff, M, Dombrowski, MP, Weiner, SJ, Moawad, AH, Northen, A, Iams, JD, Varner, MW, Caritis, SN, O'Sullivan, MJ, Miodovnik, M, Leveno, KJ, Conway, D, Wapner, RJ, Carpenter, M, Mercer, B, Ramin, SM, Thorp, JM, Peaceman, AM & Gabbe, S 2005, 'Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high-risk for preterm delivery', American Journal of Obstetrics and Gynecology, vol. 193, no. 3 SUPPL., pp. 1181-1186. https://doi.org/10.1016/j.ajog.2005.06.036
Sibai, Baha ; Meis, Paul J. ; Klebanoff, Mark ; Dombrowski, Mitchell P. ; Weiner, Steven J. ; Moawad, Atef H. ; Northen, Allison ; Iams, Jay D. ; Varner, Michael W. ; Caritis, Steve N. ; O'Sullivan, Mary J. ; Miodovnik, Menachem ; Leveno, Kenneth J. ; Conway, Deborah ; Wapner, Ronald J. ; Carpenter, Marshall ; Mercer, Brian ; Ramin, Susan M. ; Thorp, John M. ; Peaceman, Alan M. ; Gabbe, Steven. / Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high-risk for preterm delivery. In: American Journal of Obstetrics and Gynecology. 2005 ; Vol. 193, No. 3 SUPPL. pp. 1181-1186.
@article{39592cc9ab96443d8a0a949edb077e8f,
title = "Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high-risk for preterm delivery",
abstract = "Objective: The purpose of this study was to examine the utility of a single second-trimester plasma corticotropin-relasing hormone measurement as a marker for preterm delivery in women at high risk for preterm delivery. Study design: This is an analysis of data from a multicenter placebo-controlled trial designed to evaluate the role of 17 alpha hydroxyprogesterone caproate (17P) in the prevention of recurrent preterm birth. Women with a documented history of a previous spontaneous preterm birth at <37 weeks were enrolled (16-20 wks) and randomly assigned in a 2 to 1 ratio to weekly injections of 17P or matching placebo. Blood was collected before treatment in 170 patients (113 assigned 17P and 57 placebo) who were enrolled at 11 of the 19 centers. Plasma levels of corticotropin-releasing hormone were compared between those who delivered preterm and those delivering at term. Data were analyzed using the Wilcoxon rank-sum test. Results: The overall rates of preterm birth in this cohort of 170 patients were 35.9{\%} at <37 weeks (31.9{\%} progesterone, 43.9{\%} placebo), and 19.4{\%} at <35 weeks (18.6{\%} vs 21.1{\%}). The median levels of corticotropin-releasing hormone were similar between those delivering at <37 weeks and those delivering ≥37 weeks (0.39 ng/mL vs 0.37 ng/mL, P = .08). In addition, there were no differences in corticotropin-releasing hormone levels among those who delivered at <35 weeks or ≥35 weeks (0.36 vs 0.38, P = .90). Moreover, there were no differences in corticotropin-releasing hormone levels among those in the placebo group who delivered at <37 or ≥37 weeks (0.40 vs 0.41, P = .72) and at <35 or ≥35 weeks (P = .64). Conclusion: A single measurement of corticotropin-releasing hormone at 16 to 20 weeks' gestation is not a good biomarker for recurrent preterm delivery in patients at high risk for this complication.",
keywords = "CRH levels, Prediction, Preterm delivery",
author = "Baha Sibai and Meis, {Paul J.} and Mark Klebanoff and Dombrowski, {Mitchell P.} and Weiner, {Steven J.} and Moawad, {Atef H.} and Allison Northen and Iams, {Jay D.} and Varner, {Michael W.} and Caritis, {Steve N.} and O'Sullivan, {Mary J.} and Menachem Miodovnik and Leveno, {Kenneth J.} and Deborah Conway and Wapner, {Ronald J.} and Marshall Carpenter and Brian Mercer and Ramin, {Susan M.} and Thorp, {John M.} and Peaceman, {Alan M.} and Steven Gabbe",
year = "2005",
month = "9",
doi = "10.1016/j.ajog.2005.06.036",
language = "English (US)",
volume = "193",
pages = "1181--1186",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "3 SUPPL.",

}

TY - JOUR

T1 - Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high-risk for preterm delivery

AU - Sibai, Baha

AU - Meis, Paul J.

AU - Klebanoff, Mark

AU - Dombrowski, Mitchell P.

AU - Weiner, Steven J.

AU - Moawad, Atef H.

AU - Northen, Allison

AU - Iams, Jay D.

AU - Varner, Michael W.

AU - Caritis, Steve N.

AU - O'Sullivan, Mary J.

AU - Miodovnik, Menachem

AU - Leveno, Kenneth J.

AU - Conway, Deborah

AU - Wapner, Ronald J.

AU - Carpenter, Marshall

AU - Mercer, Brian

AU - Ramin, Susan M.

AU - Thorp, John M.

AU - Peaceman, Alan M.

AU - Gabbe, Steven

PY - 2005/9

Y1 - 2005/9

N2 - Objective: The purpose of this study was to examine the utility of a single second-trimester plasma corticotropin-relasing hormone measurement as a marker for preterm delivery in women at high risk for preterm delivery. Study design: This is an analysis of data from a multicenter placebo-controlled trial designed to evaluate the role of 17 alpha hydroxyprogesterone caproate (17P) in the prevention of recurrent preterm birth. Women with a documented history of a previous spontaneous preterm birth at <37 weeks were enrolled (16-20 wks) and randomly assigned in a 2 to 1 ratio to weekly injections of 17P or matching placebo. Blood was collected before treatment in 170 patients (113 assigned 17P and 57 placebo) who were enrolled at 11 of the 19 centers. Plasma levels of corticotropin-releasing hormone were compared between those who delivered preterm and those delivering at term. Data were analyzed using the Wilcoxon rank-sum test. Results: The overall rates of preterm birth in this cohort of 170 patients were 35.9% at <37 weeks (31.9% progesterone, 43.9% placebo), and 19.4% at <35 weeks (18.6% vs 21.1%). The median levels of corticotropin-releasing hormone were similar between those delivering at <37 weeks and those delivering ≥37 weeks (0.39 ng/mL vs 0.37 ng/mL, P = .08). In addition, there were no differences in corticotropin-releasing hormone levels among those who delivered at <35 weeks or ≥35 weeks (0.36 vs 0.38, P = .90). Moreover, there were no differences in corticotropin-releasing hormone levels among those in the placebo group who delivered at <37 or ≥37 weeks (0.40 vs 0.41, P = .72) and at <35 or ≥35 weeks (P = .64). Conclusion: A single measurement of corticotropin-releasing hormone at 16 to 20 weeks' gestation is not a good biomarker for recurrent preterm delivery in patients at high risk for this complication.

AB - Objective: The purpose of this study was to examine the utility of a single second-trimester plasma corticotropin-relasing hormone measurement as a marker for preterm delivery in women at high risk for preterm delivery. Study design: This is an analysis of data from a multicenter placebo-controlled trial designed to evaluate the role of 17 alpha hydroxyprogesterone caproate (17P) in the prevention of recurrent preterm birth. Women with a documented history of a previous spontaneous preterm birth at <37 weeks were enrolled (16-20 wks) and randomly assigned in a 2 to 1 ratio to weekly injections of 17P or matching placebo. Blood was collected before treatment in 170 patients (113 assigned 17P and 57 placebo) who were enrolled at 11 of the 19 centers. Plasma levels of corticotropin-releasing hormone were compared between those who delivered preterm and those delivering at term. Data were analyzed using the Wilcoxon rank-sum test. Results: The overall rates of preterm birth in this cohort of 170 patients were 35.9% at <37 weeks (31.9% progesterone, 43.9% placebo), and 19.4% at <35 weeks (18.6% vs 21.1%). The median levels of corticotropin-releasing hormone were similar between those delivering at <37 weeks and those delivering ≥37 weeks (0.39 ng/mL vs 0.37 ng/mL, P = .08). In addition, there were no differences in corticotropin-releasing hormone levels among those who delivered at <35 weeks or ≥35 weeks (0.36 vs 0.38, P = .90). Moreover, there were no differences in corticotropin-releasing hormone levels among those in the placebo group who delivered at <37 or ≥37 weeks (0.40 vs 0.41, P = .72) and at <35 or ≥35 weeks (P = .64). Conclusion: A single measurement of corticotropin-releasing hormone at 16 to 20 weeks' gestation is not a good biomarker for recurrent preterm delivery in patients at high risk for this complication.

KW - CRH levels

KW - Prediction

KW - Preterm delivery

UR - http://www.scopus.com/inward/record.url?scp=24644480139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24644480139&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2005.06.036

DO - 10.1016/j.ajog.2005.06.036

M3 - Article

C2 - 16157134

AN - SCOPUS:24644480139

VL - 193

SP - 1181

EP - 1186

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 3 SUPPL.

ER -